Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & & Johnson
JNJ, -0.19%.
stated Thursday that its lead vaccine prospect protected versus infection with SARS-CoV-2, the infection that causes COVID-19, in pre-clinical research studies. The vaccine provided a robust immune response as shown by “neutralizing antibodies,” successfully avoiding subsequent infection and supplying near-complete or total defense in the lungs from the infection in non-human primates, the business stated. Based upon the strength of the data, a Phase 1/2a first-in-human medical trial of the vaccine prospect, Ad26.COV2.S, in healthy volunteers, has now begun in the United States and Belgium, the company said. Conversations are underway with partners with the goal to begin an essential Phase 3 clinical trial of the single vaccine dosage versus placebo in September, pending the interim information of the Phase 1 and 2 trials and approval of regulators, Johnson & & Johnson stated.